You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
北京，2024年9月27日...
- VYLOY 成为欧盟首个也是目前唯一获批的靶向 CLDN18.2药物，38%的晚期胃癌患者CLDN18.2表达呈阳性1,2 - III期研究结果显示靶向...
Read more about 安斯泰来 VYLOY (佐妥昔单抗) 获欧盟批准与化疗联合用于治疗晚期胃或胃食管交界处腺癌
2023年9月17日是第五个世界患者安全日（World Patient Safety Day），本次世界患者安全日主题是“患者安全需要患者参与”。口号是“提高患者的发言权”。
Follow China news
